Please login to the form below
Actavis
The Top Pharma List rankings are compiled from GlobalData's
pharmaceutical revenue figures, which are based on prescription medicine
sales, including generics drugs.
UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med
Actavis UK also continued paying off Advanz Pharma – previously known as AMCo – after taking over sales of hydrocortisone in 2015, said the CMA. ... Actavis UK (now known as Accord UK) took over the business in 2015 and is held liable for Auden
Sanofi patent case win holds off generic rivals for key cancer drug
Companies including Actavis and Mylan have received tentative US Food and Drug Administration (FDA) approvals for copies of Jevtana in recent years.
Teva wins FDA OK for crucial migraine drug
order to pay down a very high level of debt stemming from its $39bn acquisition of Allergan’s generics business Actavis in 2015.
Axovant poaches Allergan’s and Teva’s chief medical and science officers
Most recently, Corcoran served as chief medical officer at Allergan and before that he was Actavis’ chief medical officer.
Morning brief: Roche raises outlook for 2018, ASCO abstracts revealed and more
The $64bn sum makes the deal the biggest pharma M&A transaction since Actavis bought Allergan in 2015 for $70.5bn.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
